Clinical and laboratory data
Data were compiled from the medical records that included demographics, type of clinical presentation, liver and renal function, immune status and co-medication. GFR were derived from Schwartzbedequation = 0.413 × (Ht/serum creatinine) and SchwartzCystatin C equation = 40.6 × (1.8/Cystatin C)0.93, respectively (10-12). MPA plasma concentrations were measured by ELISA using Siemens Viva-E Drug Testing System with Emit 2000 MMF Assay Test Kit (Siemens, Llanberis, UK). The quantitative linear range of MPA was 0.0~15.0 mg/L. MPA exposure expressed by area under the curve (MPA-AUC) was a part of routine clinical care which is determined based on samples collected pre dose, at 20, 60, and 180 min after dose (13). MW·Pharm++ 1.6 was used to calculate MPA-AUC0-12h. Data was entered and checked by second person verification.